Skip to content

Hypnosis: a Path to Appeasement

Hypnosis: a Path to Appeasement

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05942885
Acronym
HYCVA
Enrollment
50
Registered
2023-07-12
Start date
2023-10-30
Completion date
2026-07-30
Last updated
2025-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Cancer

Keywords

hypnosis, Diffuse large cell B-cell lymphoma, follicular lymphoma, anxiety

Brief summary

Hypnosis is a technique allowing the patient to focus his mental attention on a thought or a sensation, with the aim of reducing or modulating the intensity of a negative feeling or an ordeal encountered during the course of treatment. This tool can be used when patients are faced with chronic disorders (pain, anxiety, ...) or iatrogenic effects (nausea, asthenia, ...). The patient is referred to hypnosis care by the doctor, psychologist or paramedics who follow him, when they detect a need. Several scientific studies have shown the effectiveness of hypnosis in improving the quality of life of patients with breast cancer and in reducing pain during invasive procedures. On the other hand, in hematology, no research has measured the evolution of anxiety, over time, in patients receiving hypnotherapy.

Interventions

Patient undergoing hypnosis session will have their anxiety measured just before the third session of hypnosis and after during a telephonic consultation. The result will be compared to the anxiety level before the first hypnosis session

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over 18 years old, fluent in French. * Patients starting hypnotherapy for anxiety disorders. * Anxiety score on the HADS scale (Hospital Anxiety and Depression Scale) greater than or equal to 8/21 * Patients with diffuse large cell B-cell lymphoma or follicular lymphoma, whatever the stage of the disease. * Diagnosis announcement less than 2 months old

Exclusion criteria

* Persons deprived of their liberty by a judicial or administrative decision * Adults subject to a legal protection measure

Design outcomes

Primary

MeasureTime frameDescription
Evolution of anxietyWeek 6 after 2 hypnosis sessionsDifference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.

Secondary

MeasureTime frameDescription
Evolution of anxiety between D0 and M3 according to the type of lymphomaMonth 3 after 3 hypnosis sessionsDifference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions for two subgroups : follicular lymphoma and diffuse large b-cell lymphoma. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
Evolution of anxiety between D0 and W6 according to the type of lymphomaWeek 6 after 2 hypnosis sessionsDifference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions for two subgroups : follicular lymphoma and diffuse large b-cell lymphoma. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
Evolution of anxiety between D0 and W6 according to the gender of the patientWeek 6 after 2 hypnosis sessionsDifference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions for two subgroups : man and woman. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
Evolution of anxiety before hypnotherapy and after 3 months of follow-up in hypnotherapyMonth 3 after 3 hypnosis sessionsDifference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
Evolution of anxiety between D0 and W6 according to age categoryWeek 6 after 2 hypnosis sessionsDifference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions for two subgroups : under 60 years old ans over 60 years old. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
Evolution of anxiety between D0 and M3 according to age categoryMonth 3 after 3 hypnosis sessionsDifference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions for two subgroups : under 60 years old ans over 60 years old. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
Evolution of anxiety between D0 and M3 according to the gender of the patientMonth 3 after 3 hypnosis sessionsDifference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions for two subgroups : man and woman. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.

Countries

France

Contacts

Primary ContactThomas BERT
thomas.bert01@chu-lyon.fr04.78.86.43.45

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026